Treatment using engineered T cells targeting MAGE-A4 in advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label study designed to explore the safety, efficacy, and pharmacokinetics of T cell receptor-engineered T cells (TCR-T) that specifically target the melanoma-associated antigen-4 (MAGE-A4) in patients with advanced solid tumors. Participants will be those who have shown progression after at least one prior treatment and have tumors expressing MAGE-A4. The study will involve dose escalation to determine the optimal regimen while monitoring for adverse effects and preliminary efficacy outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18-75 year-old, male or female
2. Voluntarily willing to participate in the study and sign the written informed consent form
3. Life expectation ≥12 weeks
4. European Cooperative Oncology Group (ECOG) ≤1 at screening, 24 hours prior to apheresis (APH), lymphodepletion (LD), and infusion
5. Histologically-confirmed recurrent/metastatic advanced solid tumors
6. Radiologically-confirmed progression disease after at least one prior line of systematic treatment and no available standard of care at screening, judged by investigators
7. Fresh or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry (IHC)-stained MAGE-A4 positive
8. Human leukocyte antigen (HLA)-A\*02 allele matched
9. Per response evaluation criteria in solid tumors (RECIST) version 1.1, at least one measurable lesion
10. Adequate organ functions
11. Adequate venous access for APH
12. Non-hematological adverse events induced by previous treatment must have recovered to Grade ≤1 according to Common Terminology Criteria for Adverse Events (CTCAE), except for alopecia and peripheral neuropathy
13. Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1 year post infusion, and sperm donation is prohibited during the study
14. Women of childbearing potential must have negative serum human chorionic gonadotropin β (β-hCG) test result at screening and 48 hours prior to lymphodepletion

Exclusion Criteria:

1. Pregnant or lactating women
2. Human immunodeficiency virus (HIV) serology positive, or active hepatitis B virus (HBV)/hepatitis C virus (HCV)/Syphilis/Tuberculosis/ Coronavirus disease 2019 (COVID-19)
3. Central nerve system (CNS) metastasis must have received treatment and been neurologically stable for ≥2 months, not requiring anti-seizure medications and off steroids for ≥ 1 month prior to APH
4. Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)
5. Subjects with extensive metastases, or more rapid tumor progression prior to lymphodepletion in comparison to screening, etc. which might not be appropriate for further study treatment judged by the investigators
6. Systematic autoimmune disorders requiring long-term systematic treatment
7. Previously treated with any genetically engineered modified T cell therapy or other cell and gene therapy (CGT)
8. History of organ transplant
9. Uncontrolled or active infection within 72 hours prior to screening, APH, LD, or within 5 days prior to infusion
10. Subjects with other serious diseases that may restrict them from participating in this study
11. Clinically significant CNS disorders, such as epilepsy, stroke, Parkinson disease, etc
12. Grade ≥ 2 hemorrhage within 30 days prior to screening, or in need of longterm anticoagulants
13. Active digestive ulcer or gastrointestinal (GI) bleeding within 3 months prior to screening
14. Not satisfying wash-out period for APH
15. Previously allergic or intolerable to JWTCR001 or its components
16. Unable or unwilling to comply with the study protocol, judged by the investigators
17. Other situations implying that the subject might not be appropriate to participate in the study

Where it's running

• Department of GI Oncology,Peking University Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Lin Shen — Peking University Cancer Hospital & Institute
• Study coordinator: Lin Shen
• Email: linshenpku@163.com
• Phone: 861088196561

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SGT003 in people with advanced solid tumors

  This early-phase study tests SGT003 in adults with advanced solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of benefit.

  Recruiting Phase 1/2 Beijing Sungen Biomedical Technology Co., Ltd · Beijing, Beijing Municipality · NCT07811037

• YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors

  A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07793500

• Personalized neoantigen-pulsed dendritic cell injections for malignant solid tumors

  This study tests personalized dendritic cell injections, with or without immune checkpoint inhibitors, to see if they are safe and can help patients with advanced solid tumors.

  Recruiting ZSky Biotech Inc · Qinhuangdao, Hebei · NCT07752953

• STX-003 in advanced solid tumors given by IV, alone or with pembrolizumab

  This study tests STX-003, given by IV, to see if it is safe and potentially effective for patients with advanced solid tumors, either alone or with pembrolizumab.

  Recruiting at 4 sites Phase 1/2 Strand Therapeutics Inc. · Scottsdale, Arizona and 3 other locations · NCT07751042

• ARV-6723 alone or with pembrolizumab in adults with advanced solid tumors

  This study tests ARV-6723, by itself or with pembrolizumab, to see if it is safe and could help the immune system fight advanced solid tumors in adults.

  Recruiting at 4 sites Phase 1/2 Arvinas Inc. · New York, New York and 3 other locations · NCT07749586

• BG-85738 alone or with other anticancer drugs in RAS-mutant advanced or metastatic solid tumors

  This study tests BG-85738, alone or with other cancer drugs, in adults whose solid tumors have RAS mutations and have progressed.

  Recruiting at 3 sites Phase 1 BeOne Medicines · South Brisbane, Queensland and 2 other locations · NCT07746141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.